CEO Dumps 20 Million Ginkgo Bioworks Shares
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Stay updated with breaking news from Austin Che. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of Serbia today announced that they have entered into a Memorandum of Understanding ("MoU") with the intent of collaborating in support of Serbia's bioeconomy vision.
MRNA technology has the potential to help develop many life-saving therapeutics and vaccines.
Sensible Biotechnologies will partner with Ginkgo Bioworks to develop an in vivo microbial mRNA manufacturing platform – aiming to address a major bottleneck in mRNA manufacturing.
/PRNewswire/ -- Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA...